CTKB
Cytek Biosciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.65
−1.17%Year over year
Reported trailing growth
- Revenue
- +5.4%
- EBITDA
- —
- EBIT
- -66.2%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +4.9%
- EBITDA
- +14.5%
- EPS
- +55.0%
Three-year CAGR
- Revenue
- +7.1%
- EBITDA
- —
- EBIT
- -96.8%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026